Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Rosell R, Tonato M, Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin Oncol. 1998;25(4 Suppl 9):27–34.
   PubMed Web of Science ®Google Scholar
• Tartarone A, Lapadula V, Di Micco C, et al. Beyond conventional: the new horizon of targeted therapy for the treatment of advanced non-small cell lung cancer. Front Oncol. 2021;11:632256.
   PubMed Web of Science ®Google Scholar
• Dong J, Li B, Lin D, et al. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. 2019;10:230.
   PubMed Web of Science ®Google Scholar
• Memmott RM, Wolfe AR, Carbone DP, et al. Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J Thorac Oncol. 2021;16(7):1086–1098.
   PubMed Web of Science ®Google Scholar
• Lasala R, Santoleri F, Romagnoli A, et al. Randomized clinical trials and real-life studies: comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma. J Oncol Pharm Pract. 2022;28(4):870–883.
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – What is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.
   PubMed Web of Science ®Google Scholar
• Walker B, Boyd M, Aguilar K, et al. Comparisons of real-world time-to-event end points in oncology research. J Clin Oncol Clin Cancer Inform. 2021;5:45–46.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• Agulnik JS, Kasymjanova G, Pepe C, et al. Real-world pattern of treatment and clinical outcomes of EGFR-mutant non-small cell lung cancer in a single academic centre in Quebec. Curr Oncol. 2021;28(6):5179–5191.
   PubMed Web of Science ®Google Scholar
• Davis KL, Kaye JA, Masters ET, et al. Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with Crizotinib. Curr Oncol. 2018;25(1):e40–e49.
   PubMed Web of Science ®Google Scholar
• Gan CL, Stukalin I, Meyers DE, et al. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. Eur J Cancer. 2021;151:115–125.
   PubMed Web of Science ®Google Scholar
• Horvat P, Gray CM, Lambova A, et al. Comparing findings from a friends of cancer research exploratory analysis of real-world end points with the cancer analysis system in England. J Clin Oncol Clin Cancer Inform. 2021;5:1155–1168.
   PubMed Web of Science ®Google Scholar
• John A, Yang B, Shah R. Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced non-small cell lung cancer (aNSCLC) using Real-World electronic health record data. Adv Ther. 2021;38(3):1552–1566.
   PubMed Web of Science ®Google Scholar
• Lee J, Park S, Jung HA, et al. Evaluating entrectinib as a treatment option for non-small cell lung cancer. Expert Opin Pharmacother. 2020;21(16):1935–1942.
   PubMed Web of Science ®Google Scholar
• Lester J, Escriu C, Khan S, et al. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom. BMC Cancer. 2021;21(1):515.
   PubMed Web of Science ®Google Scholar
• Nadler E, Arondekar B, Aguilar KM, et al. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. J Cancer Res Clin Oncol. 2021;147(3):671–690.
   PubMed Web of Science ®Google Scholar
• Planchard D, Boyer MJ, Lee JS, et al. Post progression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25(7):2058–2063.
   PubMed Web of Science ®Google Scholar
• Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol. 2020;15(5):803–815.
   PubMed Web of Science ®Google Scholar
• Velcheti V, Hu X, Li Y, et al. Real-world time on treatment with first line pembrolizumab monotherapy for advanced NSCLC with PD-L1 expression ≥50%: 3-year follow-up data. Cancers. 2022;14(4):1041.
   PubMed Web of Science ®Google Scholar
• Mudad R, Patel MB, Margunato-Debay S, et al. Comparative efficacy and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. Lung Cancer. 2017;8:179–190.
   PubMedGoogle Scholar
• Weiss J, Force RW, Pugmire BA, et al. Comparative effectiveness and resource usage in patients receiving first-line taxane-based chemotherapy for stage IV Non-Small-cell lung cancer in a US community oncology setting. Clin Lung Cancer. 2017;18(4):372–380 e371.
   PubMed Web of Science ®Google Scholar
• Ganti AK, Lin CW, Yang E, et al. Real-world adherence, and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer. J Manag Care Pharm. 2022;28(3):305–314.
   Web of Science ®Google Scholar
• Lim J, Samuelsen C, Golembesky A, et al. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncol. 2019;15(13):1493–1504.
   PubMed Web of Science ®Google Scholar
• Jahanzeb M, Lin HM, Wu Y, et al. Real-world efficacy and tolerability of brigatinib in patients with non-small cell lung cancer with prior ALK-TKIs in the United States. The Oncologist. 2022;27(9):790–798.
   PubMed Web of Science ®Google Scholar
• Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clinical Trials. 1981;2(2):93–113.
   PubMedGoogle Scholar